Vaccine advisory dynamics in the U.S. face upheaval as Health Secretary RFK Jr. removed all 17 members of CDC’s Advisory Committee on Immunization Practices, sparking criticism and calls for Senate investigation. The newly appointed committee’s scientific independence is questioned amid political interference concerns. Concurrently, Merck’s FDA-approved pediatric RSV antibody enters a contentious environment with delayed advisory recommendations. These shifts may impact vaccine policy continuity, regulatory processes, and public confidence during important vaccination programs.